SECOND-LINE TREATMENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER PROGRESSED AFTER FIRST-LINE FOLFOXIRI

被引：0
|
作者：
Fornaro, Lorenzo [1 ]
Vasile, Enrico [1 ]
Masi, Gianluca [1 ]
Loupakis, Fotios [1 ]
Salvatore, Lisa [1 ]
Stasi, Irene [1 ]
Baldi, Giacomo Giulio [1 ]
Cupini, Samanta [1 ]
Barbara, Cecilia [1 ]
Pfanner, Elisabetta [2 ]
Brunetti, Isa Maura [2 ]
Di Donato, Samantha [2 ]
Caponi, Sara [1 ]
Allegrini, Giacomo [3 ]
Antonuzzo, Andrea [1 ]
Ricci, Sergio [2 ]
Chiara, Silvana [4 ]
Vitello, Stefano [5 ]
Andreuccetti, Michele [1 ]
Falcone, Alfredo [1 ,6 ]
机构：
[1] Azienda Osped Univ Pisana, Dipartimento Int Oncol Med, Azienda USL Livorno 6, Ist Toscano Tumori, Pisa, Italy
[2] Univ Pisana, Azienda Osped, UO Oncol Med 1, Ist Toscano Tumori, Pisa, Italy
[3] Azienda USL 5, UO Oncol Med, Pontedera, PI, Italy
[4] Ist Nazl Tumori, UO Oncol Med, Genoa, Italy
[5] Azienda Osped St Elia, UO Oncol Med, Caltanissetta, Italy
[6] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, I-56100 Pisa, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
    Rossini, Daniele
    Lonardi, Sara
    Antoniotti, Carlotta
    Santini, Daniele
    Tomasello, Gianluca
    Ermacora, Paola
    Germani, Marco Maria
    Bergamo, Francesca
    Ricci, Vincenzo
    Caponnetto, Salvatore
    Moretto, Roberto
    Zaniboni, Alberto
    Pietrantonio, Filippo
    Buonadonna, Angela
    Ritorto, Giuliana
    Masi, Gianluca
    Latiano, Tiziana Pia
    Rapisardi, Stefania
    Falcone, Alfredo
    Cremolini, Chiara
    BRITISH JOURNAL OF CANCER, 2021, 124 (01) : 183 - 190
  • [32] Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
    Daniele Rossini
    Sara Lonardi
    Carlotta Antoniotti
    Daniele Santini
    Gianluca Tomasello
    Paola Ermacora
    Marco Maria Germani
    Francesca Bergamo
    Vincenzo Ricci
    Salvatore Caponnetto
    Roberto Moretto
    Alberto Zaniboni
    Filippo Pietrantonio
    Angela Buonadonna
    Giuliana Ritorto
    Gianluca Masi
    Tiziana Pia Latiano
    Stefania Rapisardi
    Alfredo Falcone
    Chiara Cremolini
    British Journal of Cancer, 2021, 124 : 183 - 190
  • [33] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [34] First-line and second-line systemic treatments of patients with metastatic cutaneous melanoma (without brain metastasis) : French national guidelines
    Cupissol, D.
    Sassolas, B.
    Combemale, P.
    Modiano, P.
    Bedane, C.
    Derrey, S.
    Dygai-Cochet, I.
    Lamant, L.
    Lubrano, V.
    Mirabel, X.
    Mourregot, A.
    Bugat, M-E Rouge
    Siegrist, S.
    Thariat, J.
    Tiffet, O.
    Truc, G.
    Verdoni, L.
    Mazeau-Woynar, V.
    Planchamp, F.
    Leccia, M. T.
    ONCOLOGIE, 2014, 16 (2-3) : 137 - 147
  • [35] A phase III comparison of FOLFOXIRI to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC)
    Masi, G.
    Brunetti, I
    Murr, R.
    Benedetti, G.
    Evangelista, W.
    Picone, V
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 22 - 23
  • [36] Real-world data analysis of antiangiogenic targeted treatments in second-line following anti-EGFR antibodies and FOLFOX in first-line for patients with metastatic colorectal cancer
    Kagawa, Yoshinori
    Satake, Hironaga
    Shinozaki, Eiji
    Tanizawa, Yoshinori
    Cai, Zhihong
    Jin, Long
    Makiyama, Akitaka
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
    Qin, Shukui
    Deng, Yanhong
    Bi, Feng
    Liu, Tian Shu
    Liu, Yunpeng
    Zhang, Suzhan
    Xu, Jianming
    Shu Yongqian
    Xu, Nong
    Wu, Changping
    Wang, Xin
    Zhong, Haijun
    Feng, Jifeng
    He, Yulong
    Yang, Jianwei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Methotrexate: first-line or second-line immunomodulator?
    Fraser, AG
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (03) : 225 - 231
  • [40] First-line and second-line antiretroviral therapy
    Calmy, A
    Pascual, F
    Ford, N
    LANCET, 2004, 364 (9431): : 329 - 329
12345